Hallucinogens approved for treating psychiatric disorders: what does the science say?
A group of international experts has undertaken a critique of the clinical trials conducted to date on the value of hallucinogens in treating psychiatric disorders. Milad Fakurian/Unsplash Once sidelined in the 1970s, psychedelic substances – ranging from esketamine (a ketamine derivative) and psilocybin (the active ingredient in hallucinogenic mushrooms) to MDMA – are being reintroduced […]
Continue Reading
